Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ALLO NASDAQ:GALT NASDAQ:KERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$2.35-1.7%$1.79$0.87▼$6.37$241.90M0.861.62 million shs465,077 shsALLOAllogene Therapeutics$1.13-4.2%$1.20$0.86▼$3.78$261.82M0.355.62 million shs3.34 million shsGALTGalectin Therapeutics$4.28+0.7%$3.16$0.73▼$4.41$272.26M0.82245,112 shs176,201 shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-0.42%+5.29%+48.45%+77.70%-54.13%ALLOAllogene Therapeutics+1.72%+5.36%-15.71%+1.29%-54.09%GALTGalectin Therapeutics+6.78%+9.54%+28.79%+224.43%+48.60%KERNAkerna0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.9732 of 5 stars3.12.00.04.53.22.50.0ALLOAllogene Therapeutics2.8143 of 5 stars3.43.00.00.02.62.50.6GALTGalectin Therapeutics2.2284 of 5 stars3.50.00.00.03.53.30.0KERNAkernaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.29Hold$4.1777.30% UpsideALLOAllogene Therapeutics 2.75Moderate Buy$8.44647.30% UpsideGALTGalectin Therapeutics 3.00Buy$6.0040.19% UpsideKERNAkerna 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KERN, GALT, ALLO, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.506/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M2.37N/AN/A$0.70 per share3.36ALLOAllogene Therapeutics$20K12,536.22N/AN/A$1.55 per share0.73GALTGalectin TherapeuticsN/AN/AN/AN/A($1.86) per shareN/AKERNAkerna$13.65M0.00N/AN/A($1.52) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)ALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)KERNAkerna-$79.06M-$7.10N/AN/AN/A-339.99%N/A-113.03%N/ALatest KERN, GALT, ALLO, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GALTGalectin Therapeutics-$0.16-$0.12+$0.04-$0.12N/AN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AKERNAkernaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78ALLOAllogene TherapeuticsN/A8.928.92GALTGalectin TherapeuticsN/A1.431.43KERNAkernaN/A0.100.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ALLOAllogene Therapeutics83.63%GALTGalectin Therapeutics11.68%KERNAkerna21.97%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%ALLOAllogene Therapeutics13.20%GALTGalectin Therapeutics50.10%KERNAkerna1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableGALTGalectin Therapeutics964.06 million31.97 millionOptionableKERNAkerna11210.35 million10.23 millionNo DataKERN, GALT, ALLO, and ALEC HeadlinesRecent News About These CompaniesBanzai appoints Dean Ditto as CFOJuly 9, 2025 | msn.comMJ Freeway hit with $4.2M verdict in Pennsylvania contract disputeDecember 17, 2024 | greenmarketreport.comGPa. Jury Returns $4.2M Verdict in Medical Marijuana Program DisputeDecember 13, 2024 | law.comLFormer CNPC chairman arrested on suspicion of accepting bribes, state media saysAugust 29, 2024 | reuters.comH.C. Wainwright Sticks to Their Hold Rating for Gryphon Digital Mining (GRYP)August 24, 2024 | markets.businessinsider.comRyan Breslow’s Lead Investor Blindsided By $450 Million Bolt Fundraise: ‘We Were Never In This Deal’August 22, 2024 | forbes.comGRYP Gryphon Digital Mining, Inc.July 19, 2024 | seekingalpha.comBig Business Runs Illinois CannabisApril 14, 2024 | southsideweekly.comSAkerna: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And ExhibitsFebruary 13, 2024 | cbonds.comCAkerna Corp. Simplifies Stock Structure, Alters Fiscal YearFebruary 10, 2024 | markets.businessinsider.comAkerna Corp. Announces Completion of Strategic MergerFebruary 10, 2024 | msn.comLeading Bitcoin Miner Gryphon Digital Mining Debuts on NasdaqFebruary 9, 2024 | finance.yahoo.comGryphon Digital Mining, Inc. Debuts on NasdaqFebruary 9, 2024 | finanznachrichten.deGryphon Digital Mining Debuts on NasdaqFebruary 9, 2024 | globenewswire.comGrowerIQ buys marijuana tech firm Ample Organics from AkernaJanuary 19, 2024 | mjbizdaily.comMGrowerIQ acquires cannabis tech competitor Ample Organics from US-based AkernaJanuary 15, 2024 | betakit.comBAkerna Announces Special Meeting Date to Vote on Merger with Gryphon Digital Mining, Inc.; Effectiveness of Registration Statement on Form S-4 in Connection with MergerJanuary 10, 2024 | finance.yahoo.comAkerna Corp Ordinary SharesDecember 19, 2023 | morningstar.comM10 Effective Ways to Build Buzz Around Your BusinessDecember 12, 2023 | rollingstone.comR‘Green Wednesday’: Cannabis sales spike day before ThanksgivingNovember 23, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025KERN, GALT, ALLO, and ALEC Company DescriptionsAlector NASDAQ:ALEC$2.35 -0.04 (-1.67%) Closing price 04:00 PM EasternExtended Trading$2.35 0.00 (-0.21%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Allogene Therapeutics NASDAQ:ALLO$1.13 -0.05 (-4.24%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.01 (+1.24%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Galectin Therapeutics NASDAQ:GALT$4.28 +0.03 (+0.71%) Closing price 04:00 PM EasternExtended Trading$4.26 -0.02 (-0.49%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Akerna NASDAQ:KERNAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access